Individualized Cost-Effectiveness Analysis
Open Access
- 12 July 2011
- journal article
- essay
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 8 (7) , e1001058
Abstract
John Ioannidis and Alan Garber discuss how to use incremental cost-effectiveness ratios (ICER) and related metrics so they can be useful for decision-making at the individual level, whether used by clinicians or individual patients.Keywords
This publication has 43 references indexed in Scilit:
- Regulating direct-to-consumer genetic tests: What is all the fuss about?Genetics in Medicine, 2011
- Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou testCanadian Medical Association Journal, 2011
- High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical InterventionsAnnals of Internal Medicine, 2011
- Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalTrials, 2010
- Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysisBMJ, 2009
- Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesBMJ, 2009
- Gender differences in financial risk aversion and career choices are affected by testosteroneProceedings of the National Academy of Sciences, 2009
- Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health InterventionsPharmacoEconomics, 2007
- Switching prescription drugs to over the counterBMJ, 2004
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995